Strengths
- CB Insights lists Colossal at a $10.2B valuation.
- Company pages identify multiple public species programs.
- Company pages identify Ben Lamm, George Church and Beth Shapiro roles.
Diligence report
Colossal Biosciences
Colossal Biosciences Startup Diligence Report
The bull case is that Colossal turns frontier de-extinction R&D into defensible conservation and biotechnology IP. The diligence burden is proving scientific feasibility, ethical/regulatory permission, commercial demand and ownership of resulting technology.
Company profile
Colossal Biosciences Startup Diligence Report
Colossal Biosciences has a rare public combination of high valuation, recognizable scientific leadership and ambitious de-extinction programs, but the underwriting case is high-risk because financial quality, commercial revenue, feasibility milestones, permits, animal-welfare protocols and IP ownership are not public.
- Website
- colossal.com
- Sector
- Bioscience, genetic engineering and conservation biotechnology
- Geography
- United States
- Stage
- Private growth-stage unicorn
- Known aliases
- Colossal, Colossal Biosciences Inc., Colossal Laboratories & Biosciences
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Financial model and valuation opacity
- Scientific feasibility and milestone risk
- Commercialization uncertainty
- Regulatory, animal welfare and environmental approval risk
- IP ownership and encumbrance risk
Gaps
- Audited financials, burn, runway, cap table, investor rights and commercial revenue model.
- Scientific milestones, independent validation, embryo/surrogate outcomes and failure rates.
- Animal welfare, biosafety, environmental approvals, permits and regulatory correspondence.
- IP schedule, university/partner agreements, invention assignments and freedom-to-operate.
- Customer, licensee, partner and commercialization pipeline evidence.
Risk register
R-001: Financial model and valuation opacity
A $10.2B valuation is public, but revenue, cash, burn, cap table, investor rights and commercial model are not public.
Diligence request: Request audited financials, budget, runway, cap table and financing documents.
R-002: Scientific feasibility and milestone risk
De-extinction requires complex genetics, embryology, development, animal husbandry and conservation milestones that public pages do not validate.
Diligence request: Request program milestones, protocols, validation data, independent reviews and failure-mode analysis.
R-004: Regulatory, animal welfare and environmental approval risk
Animal research, genetic engineering, surrogate use and any ecosystem introduction could require extensive approvals and public trust.
Diligence request: Request permit matrix, biosafety review, animal-welfare protocols and counsel opinions.
R-003: Commercialization uncertainty
Public materials describe IP and commercial evolution, but no paying customer, pricing or revenue model is disclosed.
Diligence request: Request commercial roadmap, product candidates, LOIs, contracts and licensing pipeline.
R-005: IP ownership and encumbrance risk
The company says developments may be patentable, but patent schedules, university licenses and assignment rights are not public.
Diligence request: Request patent/trademark schedule, licenses, university agreements and invention assignments.
R-006: Reputational and ethical risk
De-extinction is novel and can attract ecological, animal welfare and public-trust scrutiny.
Diligence request: Review ethics board materials, stakeholder engagement, scientific advisory review and communications plan.
R-007: Partner and ecosystem dependency
Ancient DNA, conservation and animal programs likely depend on academic, zoo, veterinary and regulatory partners whose contracts are not public.
Diligence request: Request partner agreements, lab capacity, surrogate access and dependency map.
R-008: Team scaling and key-person risk
Public leadership is prominent, but execution depends on scarce scientific talent and full org capacity is not public.
Diligence request: Request org chart, hiring plan, attrition, compensation and key-person retention.
01Financial Information
Colossal has a public $10.2B unicorn valuation, but revenue, burn, cash, debt and cap-table economics are not public.
I.A Public financial information and valuation anchors
partially verified confidence: medium
CB Insights lists Colossal at a $10.2B valuation; reviewed public sources do not disclose audited financials or cap-table terms.
Evidence gaps
- Audited financials, cash, debt, burn, cap table and financing terms are private.
Hidden risks
- See R-001; public sources do not expose the underlying private records.
Follow-up questions
- Provide audited financials, budget, cap table and financing documents.
| item | public signal | verification status | diligence need |
|---|---|---|---|
| Latest CB Insights valuation | $10.2B | verified against CB Insights list | Round documents, cap table and valuation support. |
| Selected investors | Animal Capital, Breyer Capital, In-Q-Tel listed by CB Insights | verified against CB Insights list | Investor rights, ownership, preferences and strategic restrictions. |
| Financial statements | Not publicly disclosed | not publicly verifiable | Audited financials, burn, cash, debt and budget. |
I.B Revenue model, projections and capital use
not publicly verifiable confidence: high
Public materials emphasize R&D and commercialization potential, but no revenue, pricing or customer model is public.
Evidence gaps
- Revenue model, forecast, pipeline, runway and IP monetization plan are private.
Hidden risks
- See R-001; public sources do not expose the underlying private records.
- See R-003; public sources do not expose the underlying private records.
Follow-up questions
- Provide commercial roadmap, forecast model, LOIs, licensing pipeline and budget.
| financial area | public signal | diligence need |
|---|---|---|
| Commercial revenue | No paying customer or revenue disclosures found in reviewed public sources | Revenue schedule, LOIs, licensing pipeline and product roadmap. |
| Ancient DNA investment | $7.5M Ancient DNA Academic Research Project expansion | Grant agreements, milestones, IP ownership and budget controls. |
| Commercialization thesis | Company states technology/IP may create commercial applications | Business model, pricing, market validation and gross margins. |
02Products
The public product is a portfolio of de-extinction programs and enabling technologies rather than a conventional priced SKU.
II.A Product and program pipeline
partially verified confidence: medium
Public sources identify mammoth, thylacine, dodo, dire wolf, moa and related species programs, with technical milestones not public.
Evidence gaps
- Program milestones, viability data, permits and release criteria are private.
Hidden risks
- See R-002; public sources do not expose the underlying private records.
Follow-up questions
- Provide program milestone map, protocols, validation data and independent reviews.
| program | public evidence | diligence need |
|---|---|---|
| Woolly mammoth / cold-resistant elephant | Company frames first landmark project as a cold-resistant elephant with core mammoth traits | Genome-editing milestones, embryo viability, surrogate strategy and ecological criteria. |
| Thylacine | Company species page covers thylacine extinction timeline and conservation-tech claims | Marsupial developmental path, permits and partner access. |
| Dodo, dire wolf, moa and other species | Company species page lists multiple programs and ancient DNA work | Prioritization, budget, technical milestones and public acceptance. |
II.B Pricing and commercialization
not publicly verifiable confidence: high
Colossal describes potential software, wetware, hardware, IP and commercialization outputs, but no pricing or revenue model is public.
Evidence gaps
- Product pricing, target customers, LOIs and license terms are not public.
Hidden risks
- See R-003; public sources do not expose the underlying private records.
Follow-up questions
- Provide productization roadmap, customer pipeline, pricing and license agreements.
| productization path | public evidence | pricing visibility |
|---|---|---|
| Software / wetware / hardware systems | Technology page describes ancillary systems required for de-extinction | No pricing disclosed |
| IP creation | Company says many developments may be patentable | Licensing or product terms not disclosed |
| Conservation deployments | Species pages describe conservation and ecosystem outcomes | No customer or payer model disclosed |
03Customer Information
Public evidence identifies beneficiaries and partners more clearly than paying customers.
III.A Customers, beneficiaries and concentration
not publicly verifiable confidence: high
Public materials focus on conservation beneficiaries and research outputs, with no disclosed paying customer schedule.
Evidence gaps
- Paying customers, contract value, references and revenue concentration are not public.
Hidden risks
- See R-003; public sources do not expose the underlying private records.
Follow-up questions
- Provide customer/partner contracts, LOIs, references and concentration schedule.
| stakeholder | public evidence | monetization gap |
|---|---|---|
| Ecosystems and conservation beneficiaries | Company frames de-extinction around biodiversity and ecosystem support | Beneficiary is not necessarily payer. |
| Academic researchers | $7.5M Ancient DNA Academic Research Project | Grant terms and output ownership not public. |
| Commercial customers | No paying customer schedule disclosed in reviewed public sources | Revenue model and customer contracts required. |
III.B Strategic relationships and suppliers
partially verified confidence: medium
Ancient DNA, conservation and animal programs imply academic, lab, animal-care and regulatory dependencies that are not fully disclosed.
Evidence gaps
- Partner contracts, surrogate access, lab suppliers and vendor terms are private.
Hidden risks
- See R-007; public sources do not expose the underlying private records.
Follow-up questions
- Provide partner agreements, supplier map, lab capacity and data-processing contracts.
| relationship type | public evidence | diligence need |
|---|---|---|
| Academic research | Ancient DNA project under Beth Shapiro leadership | Research agreements, IP ownership and milestone governance. |
| Conservation and animal programs | Species programs imply conservation, animal husbandry and potential ecosystem partners | Permits, partner contracts, veterinary protocols and surrogate access. |
| Third-party service providers | Privacy policy states service providers may support Colossal services | Vendor contracts, data processing and lab supplier concentration. |
04Competition
Competition is not only other companies; it includes academic labs, nonprofits, conservation institutions and public-trust alternatives.
IV.A Competitive and alternative landscape
partially verified confidence: medium
Public category sources show overlap in conservation genetics, academic research and traditional conservation approaches.
Evidence gaps
- Direct IP overlap, partner conflicts and talent competition are not fully public.
Hidden risks
- See R-006; public sources do not expose the underlying private records.
Follow-up questions
- Benchmark publications, patents, partner access, grants and competing programs.
| competitor or alternative | overlap | diligence need |
|---|---|---|
| Academic conservation genomics labs | Ancient DNA, genetics and conservation science | Publication, IP and partner-access comparison. |
| Revive & Restore and nonprofit conservation genetics | De-extinction-adjacent conservation biotechnology | Partner overlap, public trust and scientific validation. |
| Traditional conservation NGOs and zoos | Species preservation and public legitimacy | Partner contracts and stakeholder acceptance. |
IV.B Basis of competition
partially verified confidence: medium
Colossal appears differentiated by high-profile science and brand, but public trust, ethics and reproducibility remain key diligence issues.
Evidence gaps
- Independent scientific review and stakeholder acceptance are private.
Hidden risks
- See R-006; public sources do not expose the underlying private records.
Follow-up questions
- Provide external advisory reviews, ethics materials and publication plan.
| axis | colossal signal | caveat |
|---|---|---|
| Scientific credibility | George Church and Beth Shapiro publicly associated | Independent review and reproducibility not public. |
| IP commercialization | Technology page claims patentable developments and commercial evolution | Patent schedule and licensing pipeline not public. |
| Public trust and ethics | Mission pages emphasize biodiversity urgency | Ethics review, animal welfare and stakeholder acceptance not public. |
05Marketing, Sales, and Distribution
Colossal public GTM is mission-led and partnership-oriented; commercial channel economics remain private.
V.A Distribution channels and GTM motions
partially verified confidence: medium
Visible GTM centers on mission storytelling, species pages, research partnerships and potential future IP commercialization.
Evidence gaps
- Sales funnel, customer pipeline, pricing and channel economics are private.
Hidden risks
- See R-003; public sources do not expose the underlying private records.
Follow-up questions
- Provide pipeline, LOIs, partnership funnel and commercialization timeline.
| channel | public evidence | revenue gap |
|---|---|---|
| Mission storytelling and species pages | Home, de-extinction and species pages explain mission and programs | No conversion to sales pipeline disclosed. |
| Scientific and academic partnerships | $7.5M ancient DNA project | Grant economics and partner obligations not public. |
| Potential IP licensing/commercialization | Technology page describes IP creation and commercialization potential | No customer, LOI, price or license schedule disclosed. |
V.B Marketing and stakeholder signals
partially verified confidence: medium
Owned pages provide strong public narrative and recruiting signals, but conversion into partnerships, grants or revenue is not public.
Evidence gaps
- Marketing reach, applicant funnel and stakeholder conversion are private.
Hidden risks
- See R-003; public sources do not expose the underlying private records.
Follow-up questions
- Provide audience metrics, partnership conversion and recruiting funnel data.
| signal | public evidence | diligence need |
|---|---|---|
| Biodiversity urgency metrics | Home page cites extinction and threatened-species metrics | Source methodology and audience conversion. |
| Species program storytelling | Species pages for mammoth, thylacine, dodo, dire wolf, moa and other programs | Scientific milestone proof and stakeholder acceptance. |
| Careers/newsletter/social channels | Careers and newsletter calls to action are public | Applicant funnel, community reach and recruiting conversion. |
06Research and Development
R&D is the core diligence workstream because scientific feasibility, IP ownership and animal welfare outcomes are not independently visible.
VI.A R&D leadership and pipeline
partially verified confidence: medium
Public sources identify notable scientific leaders and multiple species programs, but not milestone completion, protocols or failure rates.
Evidence gaps
- Milestone data, protocols, independent reviews, lab capacity and animal outcomes are private.
Hidden risks
- See R-002; public sources do not expose the underlying private records.
- See R-007; public sources do not expose the underlying private records.
Follow-up questions
- Provide R&D plan, milestones, protocols, validation data and independent scientific review.
| person or program | public role | diligence need |
|---|---|---|
| George Church | Founder | Scope of commitment, IP assignments and advisory obligations. |
| Beth Shapiro | Chief Science Officer and Ancient DNA project leader | Research governance, milestones and university/partner obligations. |
| Species pipeline | Mammoth, thylacine, dodo, dire wolf, moa and other programs | Milestone map, budget, feasibility gates and independent review. |
VI.B IP and technical defensibility
not publicly verifiable confidence: high
Public sources describe potential patentable technology and commercial evolution, but no IP schedule or freedom-to-operate analysis is public.
Evidence gaps
- Patent applications, licenses, university obligations and invention assignments are private.
Hidden risks
- See R-002; public sources do not expose the underlying private records.
- See R-005; public sources do not expose the underlying private records.
Follow-up questions
- Provide IP schedule, FTO memo, licenses, assignments and OSS/software review.
| defensibility area | public signal | private request |
|---|---|---|
| Patentable technology | Technology page says many developments may be patentable | Patent applications, assignments, encumbrances and freedom-to-operate. |
| Lab methods and protocols | High-level stack includes genetics, software, embryology and animal husbandry | Protocols, validation data, QA/QC and biosafety review. |
| Research partner outputs | $7.5M ancient DNA academic project | Publication, data rights, grants and IP ownership. |
07Management and Personnel
Public leadership is high-profile, but organizational scale, retention and key-person dependencies require private records.
VII.A Management roster and governance
verified confidence: high
Public sources identify Ben Lamm, George Church and Beth Shapiro in core leadership/science roles.
Evidence gaps
- Board composition, succession, employment terms and key-person retention are private.
Hidden risks
- See R-008; public sources do not expose the underlying private records.
Follow-up questions
- Provide org chart, board materials, employment agreements and succession plan.
| name | public role | diligence need |
|---|---|---|
| Ben Lamm | Founder and CEO | Employment agreement, equity, key-person plan and board role. |
| George Church, Ph.D. | Founder | Time commitment, university obligations, IP assignments and advisory role. |
| Beth Shapiro, Ph.D. | Chief Science Officer | Research governance, retention and partner obligations. |
VII.B Headcount and hiring signals
partially verified confidence: medium
Careers and technology pages imply a specialized multidisciplinary organization, but headcount and attrition are not public.
Evidence gaps
- Headcount by function, attrition, compensation and lab staffing are private.
Hidden risks
- See R-008; public sources do not expose the underlying private records.
Follow-up questions
- Provide HRIS export, hiring plan, compensation schedule and attrition analysis.
| signal | public evidence | diligence need |
|---|---|---|
| Careers page | Company describes itself as a bioscience and genetic engineering company advancing genomics | Open roles, headcount by function and hiring plan. |
| Scarce talent dependence | Programs require genetics, software, embryology, animal husbandry and conservation expertise | Retention, compensation and key-person exposure. |
| Turnover/attrition | Not disclosed in reviewed public sources | HRIS export, attrition analysis and employee agreements. |
08Legal and Related Matters
Legal diligence should focus on privacy, animal research, permits, environmental approvals, IP ownership and undisclosed disputes.
VIII.A Regulatory, privacy and animal-welfare obligations
partially verified confidence: medium
Privacy disclosures are public, but animal research, biosafety, environmental and species-release approvals are not public.
Evidence gaps
- Permit matrix, welfare protocols, biosafety review, environmental approvals and incident history are private.
Hidden risks
- See R-004; public sources do not expose the underlying private records.
- See R-006; public sources do not expose the underlying private records.
Follow-up questions
- Provide permit matrix, animal welfare protocols, biosafety review, privacy/security artifacts and counsel opinions.
| matter | public signal | diligence request |
|---|---|---|
| Privacy and data processing | Privacy policy lists personal, billing, device, usage, location and transaction-related data categories | Data map, subprocessors, security reports and incident history. |
| Animal research and biosafety | Public pages describe genetic engineering, embryology and animal husbandry at high level | Permits, biosafety review, welfare protocols and independent oversight. |
| Environmental or species release approvals | No public approval matrix reviewed | Regulatory roadmap, agency correspondence and ecosystem impact criteria. |
VIII.B Litigation, IP and regulatory follow-up
not publicly verifiable confidence: high
Public sources do not provide complete litigation, regulatory-action or IP schedules.
Evidence gaps
- Counsel letters, litigation schedule, regulatory correspondence and IP schedules are private.
Hidden risks
- See R-004; public sources do not expose the underlying private records.
- See R-005; public sources do not expose the underlying private records.
Follow-up questions
- Provide counsel letters, litigation/regulatory schedule, IP schedule and agency correspondence.
| diligence area | public status | request |
|---|---|---|
| Pending lawsuits and claims | No comprehensive docket or counsel letter available in reviewed materials | Counsel letter and claims schedule. |
| IP ownership and licenses | IP creation thesis public; asset schedule not public | Patent/trademark schedule, university licenses and assignment agreements. |
| Regulatory approvals | Permit matrix, animal welfare review and environmental approvals not public | Permit matrix, agency correspondence and scientific ethics review. |
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Colossal as a United States healthcare and life-sciences unicorn in Austin with a $10.2B valuation and selected investors including Animal Capital, Breyer Capital and In-Q-Tel. | verified medium | SRC-001 |
| EC-002 | Colossal describes itself as combining genetics with the business of discovery to pursue de-extinction and biodiversity-related outcomes. | verified medium | SRC-002 |
| EC-003 | Colossal says it is pursuing woolly mammoth, thylacine, dodo, dire wolf, moa and other species-related programs, with the mammoth framed as a cold-resistant elephant with core mammoth traits. | verified medium | SRC-004SRC-007 |
| EC-004 | Colossal defines functional de-extinction as generating an organism that resembles and is genetically similar to an extinct species by resurrecting lost lineage genes, engineering resistances and enhancing adaptability. | verified medium | SRC-003 |
| EC-005 | Colossal says its technology stack spans genetics, software engineering, embryology, exogenous fetal development, animal husbandry and conservation, with potential software, wetware, hardware, IP and commercialization outputs. | verified medium | SRC-005 |
| EC-006 | Colossal says it invested $7.5M to expand its Ancient DNA Academic Research Project under Chief Science Officer Beth Shapiro. | verified medium | SRC-004 |
| EC-007 | Colossal public pages identify Ben Lamm as Founder and CEO, George Church as Founder, and Beth Shapiro as Chief Science Officer. | verified high | SRC-002SRC-004 |
| EC-008 | Colossal cites biodiversity urgency metrics including 30,000 species per year on average driven to extinction and UN claims that 1,000,000 animal and plant species are threatened. | partially verified medium | SRC-002SRC-010 |
| EC-009 | Public sources did not disclose audited revenue, signed customer contracts, commercial pricing, gross margin, cash, debt, runway or customer concentration for Colossal. | not publicly verifiable high | SRC-001SRC-002SRC-005 |
| EC-010 | Colossal public materials present an IP creation and commercialization thesis but do not provide a complete patent, license or ownership schedule. | partially verified medium | SRC-005 |
| EC-011 | Colossal privacy disclosures state the company is focused on species de-extinction and collects categories including personal, billing, device, usage, location and transaction-related information through services. | verified high | SRC-008 |
| EC-012 | Public sources do not disclose comprehensive litigation, animal-research permits, environmental approvals, biosafety review, endangered-species approvals or counsel positions. | not publicly verifiable high | SRC-008 |
| EC-013 | Colossal career and company materials support an operating organization in genetics and biosciences, but headcount, attrition, compensation and lab-capacity metrics are not public. | partially verified medium | SRC-006 |
| EC-014 | Conservation genetics and de-extinction-adjacent work has nonprofit, academic and government alternatives, creating competition for talent, grants, public trust and partner access. | verified medium | SRC-005SRC-009SRC-010 |
| EC-015 | Colossal public GTM is primarily mission storytelling, species pages, education/newsletter channels, careers and scientific partnerships rather than disclosed commercial sales. | verified medium | SRC-002SRC-003SRC-004SRC-006 |
| EC-016 | Colossal public materials do not disclose animal welfare outcomes, embryo viability, surrogate capacity, ecological release criteria or independent scientific review results. | not publicly verifiable high | SRC-003SRC-004SRC-005 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | The Complete List Of Unicorn Companies | 2026-05-21 |
| SRC-002 | Colossal Biosciences | Home - Colossal | 2026-05-21 |
| SRC-003 | Colossal Biosciences | De-Extinction - Colossal | 2026-05-21 |
| SRC-004 | Colossal Biosciences | Our Species - Colossal | 2026-05-21 |
| SRC-005 | Colossal Biosciences | Science & Technology - Colossal | 2026-05-21 |
| SRC-006 | Colossal Biosciences | Careers at Colossal | 2026-05-21 |
| SRC-007 | Colossal Biosciences | Thylacine | Tasmanian Tiger - Colossal | 2026-05-21 |
| SRC-008 | Colossal Biosciences | Privacy Policy - Colossal | 2026-05-21 |
| SRC-009 | Revive & Restore | Revive & Restore | 2026-05-21 |
| SRC-010 | Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services | IPBES Global Assessment | 2026-05-21 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.